A person who received an injection with methylprednisolone acetate produced by the New England Compounding Center who developed any of the following:
- Meningitis of unknown etiology following epidural injection after May 21, 2012.
- Stroke following epidural injection after May 21, 2012, who has not received a diagnostic lumbar puncture.
- Spinal osteomyelitis or epidural abscess of unknown etiology at the site of injection following epidural or sacroiliac injection after May 21, 2012.
- Osteomyelitis or worsening inflammatory arthritis of a peripheral joint (e.g., knee) of unknown etiology diagnosed following joint injection after May 21, 2012.
A probable case with evidence of a fungal pathogen (by culture, histopathology, molecular, or antigen-based assay) associated with the clinical syndrome.
Patients under investigation:
A person who developed an infection of a normally sterile site (e.g., blood, CSF, pleural fluid, peritoneal fluid, pericardial fluid, surgical aspirate, bone, joint fluid, or internal body site (e.g., lymph node, brain)) following use of a product labeled as sterile prepared by the New England Compounding Center.